The combined effect of total body irradiation (TBI) and cyclosporin a (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation

A. Bacigalupo, V. Vitale, R. Corvö, S. Barra, T. Lamparelli, F. Gualandi, N. Mordini, G. Berisso, S. Bregante, A. M. Raiola, M. T. Van Lint, F. Frassoni

Research output: Contribution to journalArticle

Abstract

One hundred and fifty acute myeloid leukaemia (AML) patients in first remission received an allogeneic bone marrow transplant (BMT), after conditioning with cyclophosphamide 120 mg/kg and total body irradiation (TBI) 3.3 Gy x 3 (total nominal dose 9.9). The received dose, as recorded by thermoluminescent dosimeters, ranged between 7.83 and 12.25 Gy. Patients who received TBI <9.9 Gy (n=34) had a significantly higher relapse rate when compared with patients receiving ≥9.9 Gy (n=116) (43% vs. 19%; P=0.002). Graft versus host disease (GvHD) prophylaxis consisted of cyclosporin A (CyA) with or without methotrexate (MTX). The dose of CyA was either 1 or 5 mg/kg/day i.v. from day -1 to + 20, then 10 mg/kg/day orally until day + 365. Patients receiving 5 mg/kg CyA (n=40) had a higher risk of relapse (49% vs. 15%; P=0.0001). Thus, low-dose TBI (

Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalBritish Journal of Haematology
Volume108
Issue number1
DOIs
Publication statusPublished - 2000

Keywords

  • Acute myeloid leukaemia
  • Cyclosporin
  • Graft vs. leukaemia
  • Total body irradiation

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The combined effect of total body irradiation (TBI) and cyclosporin a (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation'. Together they form a unique fingerprint.

  • Cite this